News
June 6, 2023
TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-200-A0201 Targeting HPV16 to Treat Solid Tumors
June 1, 2023
TScan Therapeutics Announces Upcoming Trial in Progress Poster Presentation at the 2023 American Society of Clinical Oncology Annual Meeting
June 1, 2023
TScan Therapeutics Announces Closing of Public Offering
June 1, 2023
TScan Therapeutics to Participate in the Jefferies Healthcare Conference
May 26, 2023
TScan Therapeutics Announces Pricing of $140 Million Public Offering
May 25, 2023
TScan Therapeutics Announces Launch of Proposed Public Offering
May 24, 2023
TScan Therapeutics Appoints Gavin MacBeath, Ph.D. as Chief Executive Officer and as a Member of the Board of Directors
May 17, 2023
TScan Therapeutics Presents Preliminary Phase 1 Clinical Results on TSC-100 and TSC-101 at the American Society of Gene & Cell Therapy 26th Annual Meeting
May 10, 2023
TScan Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 9, 2023